Radiopharm takes $8M advance on R&D tax credit to fund cancer trials
What's the deal? Radiopharm TheranosticsDealroom has a profile for this one. Try Dealroom →, a clinical-stage radiopharmaceutical developer, has raised $8 million in post-IPO debt from Rockford CapitalDealroom has a profile for this one. Try Dealroom →. The facility is secured against the company's expected FY26 Australian Research and Development Tax Incentive (RDTI) and was disclosed in a filing dated October 26, 2026.
How it works: The RDTI offers eligible companies a refundable tax offset of up to 43.5%. Rockford Capital's facility lets Radiopharm draw on that expected refund early, carrying interest at a commercial rate. Repayment is due by October 27, 2027, with no penalty for paying early.
Where the money goes: Radiopharm will use the funds for its clinical trial pipeline and general working capital. It is developing radiopharmaceutical products for diagnostic and therapeutic use, with a program spanning one Phase 2 trial and five Phase 1 trials targeting lung, breast, prostate, and brain cancers.
Why now? In October, Radiopharm reported positive Phase 2b results for its lead candidate RAD101 and completed an FDA End-of-Phase 2 meeting. That makes trial execution its immediate funding need as it moves RAD101 toward a pivotal Phase 3 study.
What came before: The advance follows a roughly US$8.09M institutional placement and a share purchase plan announced in July, intended to ready RAD101 for Phase 3 and advance other pipeline programs. Unlike that raise, the Rockford facility adds cash without diluting shareholders.
What could go wrong? The $8 million is an interest-bearing advance, not a grant or equity, and must be repaid from the eventual tax refund. It underscores the company's continued reliance on external financing and future credits.
The signal: Against larger radiopharma financings such as AdvanCell's $315 million Series D, this is a modest sum. But tapping a tax-credit facility shows how clinical-stage developers stretch non-dilutive options to keep trials running between equity raises.
Read more: kalkinemedia.com
Image credit: Generated with Gemini
